Uncovering and validating molecular drug target structures remains a major bottleneck in drug development. Using the Acus unbiased genetic screening approach one can find the needle in the haystack. We specifically offer:
Deconvolution of molecular drug target structures
Unbiased validation of drug target structures
Identification of off-targets
Prediction of drug resistance mechanisms
Our high-resolution approach allows for rational drug modifications and can inform patent stratification to streamline the drug development pipeline and ultimately increase the efficacy and specificity of a targeting molecule. This will also help stratify key decisions on clinical drug developments and markedly increase the benefit to patients and the commercial value of compounds.
We offer customized screening solutions specific to relevant indications and targeting molecules!